| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 280, Issue 5, 3217-3223, February 4, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
¶****¶
From the
Departments of Medicine, ¶Cell and Developmental Biology, **Pharmacology, and Cancer Biology, Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6838 and the ||Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536
Prostaglandin E2 (PGE2) can stimulate tumor progression by modulating several proneoplastic pathways, including proliferation, angiogenesis, cell migration, invasion, and apoptosis. Although steady-state tissue levels of PGE2 stem from relative rates of biosynthesis and breakdown, most reports examining PGE2 have focused solely on the cyclooxygenase-dependent formation of this bioactive lipid. Enzymatic degradation of PGE2 involves the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The present study examined a range of normal tissues in the human and mouse and found high levels of 15-PGDH in the large intestine. By contrast, the expression of 15-PGDH is decreased in several colorectal carcinoma cell lines and in other human malignancies such as breast and lung carcinomas. Consistent with these findings, we observe diminished 15-Pgdh expression in ApcMin+/– mouse adenomas. Enzymatic activity of 15-PGDH correlates with expression levels and the genetic disruption of 15-Pgdh completely blocks production of the urinary PGE2 metabolite. Finally, 15-PGDH expression and activity are significantly down-regulated in human colorectal carcinomas relative to matched normal tissue. In summary, these results suggest a novel tumor suppressive role for 15-PGDH due to loss of expression during colorectal tumor progression.
Received for publication, September 30, 2004 , and in revised form, November 10, 2004.
* This work was supported in part by United States Public Health Service Grants RO-DK-62112 and PO-CA77839, the T. J. Martell Foundation, and the National Colorectal Cancer Research Alliance. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
Hortense B. Ingram Professor of Molecular Oncology and recipient of National Institutes of Health MERIT Award R37-DK47297. To whom correspondence should be addressed: Vanderbilt-Ingram Cancer Center, 691 Preston Research Bldg., 2300 Pierce Ave., Nashville, TN 37232-6838. Tel.: 615-343-0527; Fax: 615-936-2697; E-mail: raymond.dubois{at}vanderbilt.edu.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Hughes, T. Otani, P. Yang, R. A. Newman, R. K. Yantiss, N. K. Altorki, J. L. Port, M. Yan, S. D. Markowitz, M. Mazumdar, et al. NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non-Small Cell Lung Cancer Cancer Prevention Research, September 1, 2008; 1(4): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Holla, M. G. Backlund, P. Yang, R. A. Newman, and R. N. DuBois Regulation of Prostaglandin Transporters in Colorectal Neoplasia Cancer Prevention Research, July 1, 2008; 1(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Markowitz Colorectal Neoplasia Goes with the Flow: Prostaglandin Transport and Termination Cancer Prevention Research, July 1, 2008; 1(2): 77 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, X. Wang, Y. Lu, S. Han, F. Zhang, H. Zhai, T. Lei, J. Liang, J. Wang, K. Wu, et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer Carcinogenesis, June 1, 2008; 29(6): 1219 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bren-Mattison, A. M. Meyer, V. Van Putten, H. Li, K. Kuhn, R. Stearman, M. Weiser-Evans, R. A. Winn, L. E. Heasley, and R. A. Nemenoff Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-{gamma} in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-{kappa}B Mol. Pharmacol., March 1, 2008; 73(3): 709 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Yao, J. Xu, R. C. Harris, and M.-Z. Zhang Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase Am J Physiol Renal Physiol, February 1, 2008; 294(2): F433 - F439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lim, C. Han, L. Xu, K. Isse, A. J. Demetris, and T. Wu Cyclooxygenase-2 Derived Prostaglandin E2 Activates -Catenin in Human Cholangiocarcinoma Cells: Evidence for Inhibition of These Signaling Pathways by {omega}3 Polyunsaturated Fatty Acids Cancer Res., January 15, 2008; 68(2): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sabates-Bellver, L. G. Van der Flier, M. de Palo, E. Cattaneo, C. Maake, H. Rehrauer, E. Laczko, M. A. Kurowski, J. M. Bujnicki, M. Menigatti, et al. Transcriptome Profile of Human Colorectal Adenomas Mol. Cancer Res., December 1, 2007; 5(12): 1263 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Buchanan, V. Holla, S. Katkuri, P. Matta, and R. N. DuBois Targeting Cyclooxygenase-2 and the Epidermal Growth Factor Receptor for the Prevention and Treatment of Intestinal Cancer Cancer Res., October 1, 2007; 67(19): 9380 - 9388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yang, J. M. Amann, T. Kikuchi, R. Porta, M. Guix, A. Gonzalez, K.-H. Park, D. Billheimer, C. L. Arteaga, H.-H. Tai, et al. Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non-Small-Cell Lung Cancer Cancer Res., June 15, 2007; 67(12): 5587 - 5593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non-Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase Mol. Pharmacol., June 1, 2007; 71(6): 1715 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Sandulache, J. B. Chafin, H.-S. Li-Korotky, T. D. Otteson, J. E. Dohar, and P. A. Hebda Elucidating the Role of Interleukin 1beta and Prostaglandin E2 in Upper Airway Mucosal Wound Healing Arch Otolaryngol Head Neck Surg, April 1, 2007; 133(4): 365 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sayasith, N. Bouchard, M. Dore, and J. Sirois Cloning of equine prostaglandin dehydrogenase and its gonadotropin-dependent regulation in theca and mural granulosa cells of equine preovulatory follicles during the ovulatory process Reproduction, February 1, 2007; 133(2): 455 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Cai, Y.-T. Gao, W.-H. Chow, X.-O. Shu, G. Yang, B.-T. Ji, W. Wen, N. Rothman, H.-L. Li, J. D. Morrow, et al. Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk J. Clin. Oncol., November 1, 2006; 24(31): 5010 - 5016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tong, Y. Ding, and H.-H. Tai Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells Carcinogenesis, November 1, 2006; 27(11): 2170 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Myung, R. M. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, E. Lawrence, A. J. Dannenberg, A. K. Lovgren, G. Luo, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis PNAS, August 8, 2006; 103(32): 12098 - 12102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Wolf, J. O'Kelly, T. Rubinek, M. Tong, A. Nguyen, B. T. Lin, H.-H. Tai, B. Y. Karlan, and H. P. Koeffler 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res., August 1, 2006; 66(15): 7818 - 7823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Mann, M. G. Backlund, F. G. Buchanan, T. Daikoku, V. R. Holla, D. W. Rosenberg, S. K. Dey, and R. N. DuBois Repression of Prostaglandin Dehydrogenase by Epidermal Growth Factor and Snail Increases Prostaglandin E2 and Promotes Cancer Progression. Cancer Res., July 1, 2006; 66(13): 6649 - 6656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Celis, P. Gromov, J. M. A. Moreira, T. Cabezon, E. Friis, I. M. M. Vejborg, G. Proess, F. Rank, and I. Gromova Apocrine Cysts of the Breast: Biomarkers, Origin, Enlargement, and Relation with Cancer Phenotype Mol. Cell. Proteomics, March 1, 2006; 5(3): 462 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Otani, K. Yamaguchi, E. Scherl, B. Du, H.-H. Tai, M. Greifer, L. Petrovic, T. Daikoku, S. K. Dey, K. Subbaramaiah, et al. Levels of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-{alpha} Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G361 - G368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF]
|
|
|
|
|
|
I. Csiki, J. D. Morrow, A. Sandler, Y. Shyr, J. Oates, M. K. Williams, T. Dang, D. P. Carbone, and D. H. Johnson Targeting Cyclooxygenase-2 in Recurrent Non-Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel Clin. Cancer Res., September 15, 2005; 11(18): 6634 - 6640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman, N. Gibson, K. Subbaramaiah, and A. J. Dannenberg Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways Clin. Cancer Res., September 1, 2005; 11(17): 6097 - 6099. [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch and S. M. Lippman Advances in the Biology of Lung Cancer Chemoprevention J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
